Jump to main content
Jump to site search

Issue 9, 2018
Previous Article Next Article

Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

Author affiliations

Abstract

The potential utility of circulating tumour DNA (ctDNA) in patient blood for cancer diagnostics and real-time monitoring of disease progression is highly recognized. However, the lack of automated and efficient methods for cell-free DNA (cfDNA) isolation from peripheral blood has remained a challenge for broader acceptance of liquid biopsy in general clinical settings. Here, we demonstrate a lab-on-a-disc system equipped with newly developed, electromagnetically actuated, and reversible diaphragm valves that allows fully automated and rapid (<30 min) isolation of cfDNA from whole blood (>3 ml) to achieve high detection sensitivity by minimizing the degradation of fragile ctDNA as well as contamination of wild-type DNA from abundant blood cells. As a proof of concept study, we used the lab-on-a-disc to isolate cfDNA from patients with non-small cell lung cancer and successfully detected epidermal growth factor receptor gene mutations (L858R, T790M) during targeted drug therapy. The proposed lab-on-a-disc enables a fully automated, rapid, and point-of-care cfDNA enrichment starting from whole blood to facilitate the wide use of liquid biopsy in routine clinical practice.

Graphical abstract: Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

Back to tab navigation

Supplementary files

Article information


Submitted
09 Feb 2018
Accepted
09 Apr 2018
First published
09 Apr 2018

Lab Chip, 2018,18, 1320-1329
Article type
Paper

Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring

C. Kim, J. Park, V. Sunkara, T. Kim, Y. Lee, K. Lee, M. Kim and Y. Cho, Lab Chip, 2018, 18, 1320
DOI: 10.1039/C8LC00165K

Social activity

Search articles by author

Spotlight

Advertisements